On March 29, 2017 Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells (UCART), reported that data on its gene-edited allogeneic CAR T-cells will be presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting (Filing, 6-K, Cellectis, MAR 29, 2017, View Source [SID1234518310]). This includes both wholly-controlled Cellectis programs and Pfizer/Cellectis collaboration programs. The meeting will be held from April 1st to April 5th, 2017 in Washington, D.C., USA. Schedule your 30 min Free 1stOncology Demo! Cellectis presentation:
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
UCART22: An Allogeneic Adoptive Immunotherapy for Leukemia Targeting CD22 with CAR T-cells
Agnès Gouble1, Cécile Schiffer-Mannioui1, Séverine Thomas1, Anne-Sophie Gautron1, Laurent Poirot1, Julianne Smith2.
1Cellectis, Paris, France; 2Cellectis, New York, NY
Innate Effectors in Immunity to Cancer session – section 30
April 4, 2017, 8:00 AM – 12:00 PM Eastern Time
Pfizer/Cellectis presentations:
Allogeneic EGFRvIII Chimeric Antigen Receptor T Cells for Treatment of Glioblastoma
Oi Kwan Wong1, Mathilde Dusseaux2, Jing-Tyan Ma1, Melinda Au1, Sophie Leduc2, Joyce Chou1, Jessica M. Yu1, Marjorie Bateman1, Thomas Pertel1, Kevin C. Lindquist1, Julianne Smith3, Barbra Sasu1, Shu-Hui Liu1.
1Pfizer Inc., South San Francisco, CA; 2Cellectis, Paris, France; 3Cellectis, New York, USA
Innate Effectors in Immunity to Cancer session – section 30
April 4, 2017, 8:00 AM – 12:00 PM Eastern Time
Differential modulation of the PD-1 pathway impacts the anti-tumor activity of CAR T cells
Regina J. Lin1, Anne-Sophie Gautron2, Laurent Poirot2, Oi Kwan Wong1, Barbra Sasu1, Bijan Boldajipour1.
1Pfizer, South San Francisco, CA; 2Cellectis, Paris, France; 3Cellectis, New York, USA
Late-Breaking Research: Immunology session – section 35
April 4, 2017, 8:00 AM – 12:00 PM Eastern Time
Collaboration with Pfizer
In June 2014, Cellectis and Pfizer began collaborating on a joint clinical development program for UCAR-T therapies, in the field of oncology, directed at numerous targets selected by Pfizer and several targets selected by Cellectis.